Working... Menu

Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma (BOOST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01405573
Recruitment Status : Terminated (lack of enrolment)
First Posted : July 29, 2011
Last Update Posted : March 28, 2017
Information provided by (Responsible Party):
National Cancer Institute, Naples

Brief Summary:
The purpose of this study is to to compare the addition of sorafenib (800 mg/day)to best supportive care with best supportive care alone in terms of survival in patients with hepatocellular carcinoma (HCC) with impaired liver function (Child B).

Condition or disease Intervention/treatment Phase
Advanced Adult Hepatocellular Carcinoma Other: Best Supportive Care Drug: sorafenib Phase 3

Detailed Description:
Hepatocellular carcinoma (HCC) is the third cause of death for cancer in the world with an increasing incidence. No systemic therapy has proven effective in patients with advanced HCC until 2007, when results of the SHARP trial were presented. In this trial, the orally active multi-kinase inhibitor sorafenib (800 mg/day) significantly prolonged survival compared with placebo in patients with advanced HCC and good liver function (Child A). The same authors concluded that the effect of the drug in the population of patients with more impaired liver function should be further studied.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sorafenib in the First Line Treatment of Advanced Hepatocellular Carcinoma With Child-Pugh Liver Function Class B: Multicentre Phase 3 Randomized Trial
Study Start Date : July 2011
Actual Primary Completion Date : March 2017
Actual Study Completion Date : March 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: A: Best Supportive Care
best supportive care
Other: Best Supportive Care
Therapy given according to clinical practices at participating centres. Experimental therapies not permitted.

Experimental: B: Sorafenib 400 mg, twice a day + Best Supportive Care
sorafenib + best supportive care
Other: Best Supportive Care
Therapy given according to clinical practices at participating centres. Experimental therapies not permitted.

Drug: sorafenib
400 mg twice a day

Primary Outcome Measures :
  1. overall survival [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. worst grade toxicity per patient [ Time Frame: every 4 weeks ]
    worst grade toxicity (according to Common Terminology Criteria for Adverse Events version 4.03) per patient in both treatment arms

  2. quality of life [ Time Frame: every 4 weeks for 6 months ]
  3. progression free survival [ Time Frame: every 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with diagnosis of hepatic cell carcinoma (HCC) according to the AASLD- EASL criteria
  • Age >18 years
  • Advanced stage of disease defined as HCC not eligible for locoregional treatments (ab initio or following progression after such treatments)
  • Liver function classified as Child-Pugh class B
  • ECOG performance status < or = 2
  • Life expectancy of at least 2 months
  • Adequate contraception for fertile male and female patients
  • Signed informed consent

Exclusion Criteria:

  • Prior exposure to sorafenib or antiangiogenesis drugs
  • Concomitant diseases that contraindicate the use of sorafenib
  • Gastro-intestinal bleeding in the previous 30 days
  • Altered renal function(creatinine > 1.5 x ULN), or haematological function (platelet count < 60 x 10^9/L, hemoglobin < 9 g/dl)
  • Serious active infections (> grade 2 CTCAE version 3.0)
  • Congestive heart failure, history of congestive heart failure, unstable angina pectoris, myocardial infarct or significant valvular heart disease or uncontrolled heart arrhythmia
  • Patients who are unable or unwilling to participate in the study
  • Pregnant or lactating females
  • Hepatic encephalopathy of any grade

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01405573

Layout table for location information
Azienda Ospedaliera G. Rummo
Benevento, BN, Italy
Policlinico Giaccone
Palermo, PA, Italy, 90127
S. Orsola-Malpighi
Bologna, Italy
Ospedale Ramazzini di Carpi
Carpi, Italy
Osp. Civile Infermi
Faenza, Italy
Azienda Ospedaliera Careggi
Firenze, Italy
IRCCS-Azienda Ospedaliera Universitaria San Martino-IST
Genova, Italy
AO C. Poma
Mantova, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Italy
A.O.U. G.Martino- Policlinico Universita di Messina
Messina, Italy
Istituto Nazionale Tumori
Milano, Italy
A.O.U. Federico II
Napoli, Italy
AOU II Università di Napoli
Napoli, Italy
Istituto Nazionale dei Tumori
Napoli, Italy
Ospedale Cardarelli
Napoli, Italy
Azienda Ospedaliera Universitaria di Padova
Padova, Italy
Istituto Oncologico Veneto
Padova, Italy
A.O. Ospedali Riuniti Villa Sofia-Cervello
Palermo, Italy
Azienda Ospedaliero Universitaria di Parma
Parma, Italy
Ospedale Guglielmo da Saliceto
Piacenza, Italy, Italy
AO S. Carlo
Potenza, Italy
Policlinico Universitario Tor Vergata
Roma, Italy
Oncologia IRCCS - Casa Sollilevo Sofferenza
S. Giovanni Rotondo, Italy
Azienda Ospedaliera Universitaria Arcispedal, U.O. di Oncologia Clinica
Sant'Anna di Ferrara, Italy
A.O. Trevigilio - Caravaggio
Trevigilio, Italy
Sponsors and Collaborators
National Cancer Institute, Naples
Layout table for investigator information
Principal Investigator: Bruno Daniele, M.D. Azienda Sanitaria Rummo, Benevento, Division of Medical Oncology
Principal Investigator: Francesco Perrone, M.D., Ph.D National Cancer Institute Naples, Italy; Director Clinical Trials Unit
Principal Investigator: Ciro Gallo, M.D., Ph.D Second University of Naples, Italy; Chair of Medical Statistics
Principal Investigator: Antonio Gasbarrini, M.D. Università Cattolica del S. Cuore, Policlinico Gemelli, Roma
Principal Investigator: Giacomo Carteni', M.D. Ospedale Antonio Cardarelli, Napoli

Layout table for additonal information
Responsible Party: National Cancer Institute, Naples Identifier: NCT01405573     History of Changes
Other Study ID Numbers: BOOST
EudraCT number 2009-013870-42 ( Registry Identifier: EudraCT )
First Posted: July 29, 2011    Key Record Dates
Last Update Posted: March 28, 2017
Last Verified: March 2017

Keywords provided by National Cancer Institute, Naples:
Child Pugh B
first line

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action